Published: 1 June 2017

Publications

Recent Approvals of Medicines Containing a New Active Ingredient


Prescriber Update 38(2): 28
June 2017

For period 16 January 2017 to 15 April 2017

Trade Name (active ingredient)* Dose form and strength Therapeutic area
Descovy (emtricitabine/ tenofovir) Tablet 200 mg/10 mg and 200 mg/25 mg HIV-1 infection
Eliriduc/Golyra/Praluent (alirocumab)§ Solution for injection 75 mg/mL and 150 mg/mL Hypercholesterolaemia
Ilevro (nepafenac) Eye drops, suspension 0.3% Postoperative pain and inflammation associated with cataract surgery
Perjeta (pertuzumab) Concentrate for infusion 420 mg/14 mL HER2-positive breast cancer
Tecentriq (atezolizumab)# Concentrate for infusion 1,200 mg/20 mL Metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma

* New active ingredient shown in bold type

The new active ingredient in Descovy is tenofovir alafenamide fumarate (TAF), which replaces tenofovir disoproxil fumarate (TDF) in the related product Truvada

§ Not available

# Provisional consent

The data sheets for currently marketed prescription medicines are published on the Medsafe website (www.medsafe.govt.nz/profs/Datasheet/dsform.asp).

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /